Samantha Jaglowski, MD

Publications

• Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.

  (Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA.) J Clin Oncol. 2024 Mar 29:JCO2400033 PMID: 38552193 03/29/2024

• A phase 2 trial of CD24Fc for prevention of graft-versus-host disease.

  (Magenau J, Jaglowski S, Uberti J, Farag SS, Riwes MM, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun T, Devenport M, Lu S, Banerjee B, DaSilva C, Devine S, Zhang MJ, Burns LJ, Liu Y, Zheng P, Reddy P.) Blood. 2024 Jan 04;143(1):21-31 PMID: 37647633 PMCID: PMC10934299 SCOPUS ID: 2-s2.0-85173140340 08/30/2023

• Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor.

  (Crees ZD, Rettig MP, Bashey A, Devine SM, Jaglowski S, Wan F, Zhou A, Harding M, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Grossman BJ, Westervelt P, DiPersio JF, Uy GL.) Blood Adv. 2023 Sep 26;7(18):5210-5214 PMID: 37327120 PMCID: PMC10500469 06/16/2023

• Cell Therapy Informatics: Updates on the Integration of HCT/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safety, Research, and Data Interoperability.

  (Ho VT, Klumpp TR, Liang WH, Prestegaard M, Horwitz M, Hamilton BK, Page K, Jaglowski S, Huber J, Martinez C, Shenoy V, Chen A, Rizzo D.) Transplant Cell Ther. 2023 Sep;29(9):539-547 PMID: 37379969 SCOPUS ID: 2-s2.0-85165030784 06/29/2023

• A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma.

  (Shouse G, Kaempf A, Gordon MJ, Artz A, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski S, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV.) Blood Adv. 2023 Jul 25;7(14):3516-3529 PMID: 36735393 PMCID: PMC10362276 02/04/2023

• Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine.

  (Himed S, Chung C, Dulmage B, Jaglowski S, Bond D, Maddocks K, Kaffenberger BH.) J Eur Acad Dermatol Venereol. 2023 Jul;37(7):e890-e893 PMID: 36800311 02/18/2023

• Cutaneous graft-versus-host disease within chronic photodamaged skin: A case series demonstrating role for topical 5-fluorouracil.

  (Gray AN, Avila C, Chung CG, Seminario-Vidal L, Mims A, Dulmage B, Larkin K, Choe H, Jaglowski S, Vasu S, Kaffenberger BH.) JAAD Case Rep. 2023 Jun;36:82-88 PMID: 37250015 PMCID: PMC10220457 05/30/2023

• Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

  (Chakraborty R, Yi J, Rybicki L, Preussler J, Deol A, Loren A, Savani B, Jim HSL, Cerny J, Reynolds J, Whitten J, Wingard JR, McGuirk JP, Uberti J, Khera N, Stiff P, Jaglowski SM, Hashmi S, Holtan SG, Devine S, Hahn T, Whalen VL, Saber W, Wood W, Baker KS, Syrjala K, Majhail NS.) Transplant Cell Ther. 2023 Jun;29(6):388.e1-388.e6 PMID: 36870388 PMCID: PMC10718487 SCOPUS ID: 2-s2.0-85153345405 03/05/2023

• Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents.

  (Faisal MS, Hanel W, Voorhees T, Li R, Huang Y, Khan A, Bond D, Sawalha Y, Reneau J, Alinari L, Baiocchi R, Christian B, Maddocks K, Efebera Y, Penza S, Saad A, Brammer J, DeLima M, Jaglowski S, Epperla N.) Cancer Med. 2023 Apr;12(7):8228-8237 PMID: 36653918 PMCID: PMC10134314 01/20/2023

• Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors.

  (Hong S, Zhao J, Wang S, Wang H, Lee JH, Farhadfar N, McGuirk JP, Savani BN, Shahrukh HK, Stiff P, Khera N, Hahn T, Loren AW, Jaglowski SM, Wood WA, Saber W, Cerny J, Holtan SG, Reynolds JM, Deol A, Jim H, Uberti J, Whalen V, Yi JC, Preussler J, Baker KS, Shaw BE, Devine S, Syrjala K, Majhail NS, Wingard JR, Al-Mansour Z.) Transplant Cell Ther. 2023 Mar;29(3):202.e1-202.e8 PMID: 36427784 PMCID: PMC10165614 SCOPUS ID: 2-s2.0-85146977106 11/26/2022

• A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.

  (Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L.) Cancers (Basel). 2023 Feb 24;15(5) PMID: 36900230 PMCID: PMC10000669 03/12/2023

• Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience.

  (Jiang J, Sigmund AM, Zhao Q, Elder P, Benson DM, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N.) Cancers (Basel). 2022 Nov 14;14(22) PMID: 36428678 PMCID: PMC9688916 11/27/2022